47 search results for: coexisting diseases

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

Learn from Prof. Papadopoulou as she highlights the importance of collaboration of multiple specialties in the care of pediatric EoE.

Learn about key drivers of type 2 inflammation in EoE and how they mediate progressive esophageal remodeling and impact patient burden